Gettinger SN, Horn L, Gandhi L, et al :Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 33: 2004-2012, 2015
Weber JS, D'Angelo SP, Minor D, et al :Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037) a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16 :375-384, 2015
Robert C, Long GV, Brady B, et al :Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 372 : 320-330, 2015
Hodi FS, O'Day SJ, McDermott DF, et al :Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 363 :711-723, 2010
Hughes J, Vudattu N, Sznol M, et al :Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 38: e55-57, 2015